The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program -Pre-Clinical, 2026CSM-101 TRPML1 Agonist for Parkinson’s Disease
Study Rationale:
The appropriate regulation of proteins and lipids within neurons is critical for human health. Lysosomes are specialized structures within cells that are responsible...
-
Research Grant, 2026Expansion of the NEULARK Study, Examining the Effects of NEU-411 on LRRK2-driven Parkinson’s Patients, Into Israel
Study Rationale:
LRRK2 is a gene that plays a role in the development and progression of Parkinson's disease (PD). Mutations in the LRRK2 gene can increase the risk of developing PD...
-
Research Grant, 2026Differential Expression of Aging-related Genes and Co-expression with SNCA and MAPT in Parkinson’s Disease Patients and Healthy Controls
Study Rationale:
Aging is the strongest risk factor for Parkinson’s disease, yet the biological reasons behind this connection remain unclear. Our recent findings suggest that...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biomarkers, 2026Metabolomic Biomarkers of PD Progression
Study Rationale:
We have identified small molecules associated with altered odds of having Parkinson's disease (PD) among hundreds of metabolites measured in metabolomic analyses of...
-
Research Grant, 2026α-Synuclein Pathology Beyond Lewy-related Pathology: α-synuclein Oligomers and Seeding Activity in LRRK2-related Parkinson’s Disease
Study Rationale:
Parkinson's disease is caused by the buildup of a protein called α-synuclein in brain cells, and, in most patients, this protein forms large clumps called Lewy...
-
Fall 2025 RFP: Data Advice To Action, 2026Identifying Blood-Based Proteomic Biomarkers of Cognitive Decline and its Pathological Heterogeneity in PD and DLB
Study Rationale:
Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) both feature debilitating cognitive decline without reliably effective therapies. This dearth of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.